Overview

Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see what changes happen to the tumors while taking the axitinib and after it is stopped (during the scheduled breaks), and what changes in the tumor may be responsible for this growth. This will be done by using a special kind of scan called an 18F-FLT PET/CT. In addition, the investigators want to find out how the drugs are processed and distributed in the human body. The investigators will also look at how different types of cancer are affected by axitinib. The investigators will also correlate vasculature kinetics extracted from the dynamic FLT PET/CT imaging with the vasculature kinetics extracted from DCE-CT.
Phase:
Phase 1
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborator:
Pfizer
Treatments:
Axitinib